Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
thrombolytic therapy · 1 trial · 6 indications
| Name | Type | Description |
|---|---|---|
| angioplasty, transluminal, percutaneous coronary | PROCEDURE | - |
| coronary artery bypass | PROCEDURE | - |
| thrombolytic therapy | DRUG | - |
Men and women with myocardial infarction and cardiogenic shock.
Thrombolytic therapy is used for cardiovascular diseases, specifically in the context of coronary disease, myocardial infarction, and cardiogenic shock. It is a small molecule treatment being studied to address these serious heart conditions, with the goal of improving outcomes for patients experiencing these acute cardiovascular events.
Thrombolytic therapy is being developed by Elevance Health, Inc., a company traded on the stock exchange under the ticker symbol ELV. The company is conducting clinical research on this treatment for cardiovascular diseases, focusing on its potential role in managing conditions such as myocardial infarction and cardiogenic shock.
Thrombolytic therapy is in Phase 3 clinical development. This late-stage phase indicates that the treatment is being evaluated in a larger patient population to confirm its efficacy and monitor for adverse effects, building on earlier studies. It remains investigational and has not yet been approved for general use.
Thrombolytic therapy has been studied in a completed Phase 3 clinical trial identified as NCT00000552, titled "Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock." This trial focused on patients with cardiovascular diseases, including coronary disease and cardiogenic shock, and enrolled adults aged 18 years and older.
Thrombolytic therapy is the treatment evaluated in the Shock Trial, formally known as NCT00000552. This trial investigated whether emergent revascularization of occluded coronary arteries benefits patients with cardiogenic shock. The therapy was studied in this context as part of its Phase 3 clinical development for cardiovascular diseases.